Intra-Cellular Therapies, New York, NY

Intra-Cellular Therapies

www.intracellulartherapies.com

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being ...

More>>

Number of Employees: 100-250
Annual Revenue: $10-50 Million

www.intracellulartherapies.com
430 East 29th Street Suite 900
New York, NY USA 10016
Phone: 646.440.9333

Similar Companies

Kelyniam

Our mission at Kelyniam is to apply 3D printing and rapid prototyping technology to create innovative medical products that improve the lives of physicians and their patients.

Medican Enterprises Inc.

Medican Enterprises is a bio-pharmaceutical company focused on developing, distributing and marketing pharmaceutical grade cannabis to the emerging global medical marijuana market. It’s wholly owned subsidiary Medican Systems Inc. is an industry leader in the design, construction and operation of Medical Marijuana and Cultivation Centers across Canada and the United States. Traded on the OTCBB, Medican drives shareholder value through its scalable business model and commitment to scientific research, operational excellence and regulatory compliance.

CTOs on the Move